77 related articles for article (PubMed ID: 2314826)
1. Dose and schedule effects of cisplatin on the related acute iron changes.
Pollera CF; Ameglio F; Nardi M; Marolla P; Carlini P; Frasca AM
Oncology; 1990; 47(2):133-8. PubMed ID: 2314826
[TBL] [Abstract][Full Text] [Related]
2. The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy.
Malik IA; Khan ZK; Hakimali A; Sabih M; Rehman G
J Pak Med Assoc; 1998 May; 48(5):127-31. PubMed ID: 9813972
[TBL] [Abstract][Full Text] [Related]
3. Early and late hyperferremia during cisplatin chemotherapy.
Sartori S; Nielsen I; Masotti M; Malacarne P
J Chemother; 1991 Feb; 3(1):45-50. PubMed ID: 2019863
[TBL] [Abstract][Full Text] [Related]
4. [Changes in blood iron levels during cisplatin chemotherapy. Preliminary results].
Sartori S; Nielsen I; Malacarne P
Medicina (Firenze); 1990; 10(1):48-9. PubMed ID: 2381283
[TBL] [Abstract][Full Text] [Related]
5. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
6. Comparison of reticulocyte hemoglobin equivalent with traditional markers of iron and erythropoiesis in pediatric dialysis.
Davidkova S; Prestidge TD; Reed PW; Kara T; Wong W; Prestidge C
Pediatr Nephrol; 2016 May; 31(5):819-26. PubMed ID: 26667237
[TBL] [Abstract][Full Text] [Related]
7. Serum transferrin receptor, ferritin, and reticulocyte maturity indices during the first year of life in 'large' preterm infants.
Schiza V; Giapros V; Pantou K; Theocharis P; Challa A; Andronikou S
Eur J Haematol; 2007 Nov; 79(5):439-46. PubMed ID: 17916083
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 2-week versus 4-week dosing intervals of epoetin beta pegol on erythropoiesis and iron metabolism in hemodialysis patients.
Morikami Y; Fujimori A; Okada S; Kumei M; Mizobuchi N; Sakai M
Ther Apher Dial; 2014 Oct; 18(5):414-20. PubMed ID: 24456373
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
Cheung WK; Goon BL; Guilfoyle MC; Wacholtz MC
Clin Pharmacol Ther; 1998 Oct; 64(4):412-23. PubMed ID: 9797798
[TBL] [Abstract][Full Text] [Related]
10. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians.
Rimon E; Kagansky N; Kagansky M; Mechnick L; Mashiah T; Namir M; Levy S
Am J Med; 2005 Oct; 118(10):1142-7. PubMed ID: 16194646
[TBL] [Abstract][Full Text] [Related]
11. Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.
Deira J; González-Sanchidrián S; Polanco S; Cebrián C; Jiménez M; Marín J; Gómez-Martino JR; Fernández-Pereira L; Tabernero J
Ren Fail; 2016 Aug; 38(7):1076-81. PubMed ID: 27197731
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two iron gluconate treatment modalities in chronic hemodialysis patients: results of a randomized trial.
Giordano A; Arrigo G; Lavarda F; Colasanti G; Petrini C
J Nephrol; 2005; 18(2):181-7. PubMed ID: 15931646
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
14. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.
Kakimoto-Shino M; Toya Y; Kuji T; Fujikawa T; Umemura S
Ther Apher Dial; 2014 Oct; 18(5):421-6. PubMed ID: 24456328
[TBL] [Abstract][Full Text] [Related]
15. Changes in serum iron levels following very high-dose cisplatin.
Pollera CF; Ameglio F; Reina S; Nardi M; Abbolito MR; Parracino C
Cancer Chemother Pharmacol; 1987; 19(3):257-60. PubMed ID: 3581420
[TBL] [Abstract][Full Text] [Related]
16. The relationship between red blood cell and reticulocyte indices and serum markers of iron status in the cord blood of newborns.
Ervasti M; Kotisaari S; Sankilampi U; Heinonen S; Punnonen K
Clin Chem Lab Med; 2007; 45(8):1000-3. PubMed ID: 17579565
[TBL] [Abstract][Full Text] [Related]
17. Reticulocyte subpopulations and reticulocyte maturity index (RMI) rise as body iron status falls.
Choi JW; Pai SH
Am J Hematol; 2001 Jun; 67(2):130-5. PubMed ID: 11343386
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of intermittent iron treatment of two- to six-year-old Jordanian children with iron-deficiency anemia.
Faqih AM; Kakish SB; Izzat M
Food Nutr Bull; 2006 Sep; 27(3):220-7. PubMed ID: 17542112
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
20. Serum ferritin in refractory anemias.
Solomon LR; Hillman RS; Finch CA
Acta Haematol; 1981; 66(1):1-5. PubMed ID: 6794292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
